For example, a trifunctional natural killer cell engager (TriKEs) targeting the AML antigen, CD123, while simultaneously binding NKp46 and CD16a on NK cells has demonstrated efficacy in murine models and nonhuman primates (232) and is currently being tested in early clinical trials (NCT05086315). Here, NCR1 is linked to acute myeloid leukemia.